Volpara Solutions Launches Two New Products at RSNA

CHICAGO, Nov. 27, 2017 /PRNewswire/ -- Volpara Solutions, Inc. announced today the launch of two new products designed to help maintain consistent quality in breast screening and help identify women who may be at high risk of developing cancer, here, at the 103rd Annual Radiological Society of North America (RSNA) meeting, November 26-December 1, 2017. (South #2571). The company is introducing VolparaEnterprise Live!, a mammography quality control tool that provides the technologist with real-time, quality feedback at the gantry, and VolparaRisk software, which is designed to help identify high risk women based on factors other than family history who might be overlooked otherwise.

Designed to help technologists acquire consistent, high quality mammograms, VolparaEnterprise Live! calculates the patient positioning score, dose, and compression pressure for each image within 30 seconds of acquisition. Pending regulatory approval, VolparaEnterprise Live! puts quality data in the technologists' hands before the patient leaves the room. This helps reduce technical recalls and retakes and promote mammography quality.

As the majority of breast cancer patients have no, or minimal, family history of breast cancer, reliance on traditional family history pathways does not capture all high-risk women. VolparaRisk software helps identify those women who may be at increased risk of developing breast cancer, irrespective of family history, and may benefit from a full risk assessment work-up. VolparaRisk software, available on the VolparaEnterprise Breast Imaging metrics platform, applies data ranking once the Volpara clinical applications process the mammogram. Each mammogram is ranked according to the magnitude of the mammographic density relative to the woman's age and breast size. This helps identify additional women who can be directed to the facility's high-risk clinic, and potentially, to supplemental screening.

VolparaEnterprise software is the only solution currently available that provides comprehensive assessment of image quality on every mammography or tomosynthesis study, including patient positioning and compression. It provides automated ConstantQuality™ performance monitoring through dynamic, interactive dashboards that drive technologist training and quality improvement programs. Additionally, it has been designed to help facilities comply with the FDA's new EQUIP inspection program. At RSNA, Volpara will expand its EQUIP offering to include streamlined analytics of Interpreting Physician activity, in accordance with EQUIP guidelines.

Volpara will also showcase its new Volpara^®Enterprise™ DDP software. The VolparaEnterprise Clinical Applications software package offers access to VolparaDensity, VolparaDose and VolparaPressure, in a SaaS subscription model for the first time. Volpara Solutions will showcase its entire suite of quantitative breast imaging tools, which allow for personalized measurements of volumetric breast density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening. VolparaEnterprise Clinical Applications provide quick, automated assessment of every mammography and tomosynthesis exam and produces a Volpara Scorecard for every patient. with the following data:

• VolparaDensity, the most clinically validated 3D Density solution, is in use at sites across the globe helping radiologists assess breast density more objectively and helping them better consider who might benefit from additional screening.
• VolparaDose helps understand the X-ray dose delivered to the patient, based on her specific breast density. VolparaDose is computed based on the patient's breast composition and provides a personalized dose measure because no two women are alike.
• VolparaPressure helps evaluate the effectiveness of the mammogram and to better understand the patient experience.  VolparaPressure helps monitor and optimize pressure during mammography exams, which is important to decrease the discomfort experienced by women and to optimize screening outcomes.

"Building on the foundation of reproducible, accurate assessment of volumetric breast density, Volpara continues to develop new ways to deliver robust performance, quality and cancer detection data to radiologists to make better decisions about each patient's personalized screening needs," said Ralph Highnam, PhD, Volpara Chief Scientist and CEO. "We are pleased to introduce VolparaRisk software and VolparaEnterprise Live! at RSNA and look forward to working with leading breast imagers to optimize their clinical utility."

About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand. Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaEnterprise is a suite of quantitative breast imaging tools for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning and other factors designed to provide critical insight for breast imaging workflow. For more information, visit www.volparasolutions.com.

SOURCE Volpara Solutions

Related Links

http://www.volparasolutions.com